Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
G
095700
vs
K
KOSPI 200
Over the past 12 months, Genexine Inc has underperformed KOSPI 200, delivering a return of -55% compared to KOSPI 200's +119% growth.
Stocks Performance
095700 vs KOSPI 200
Performance Gap
095700 vs KOSPI 200
Performance By Year
095700 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Genexine Inc
Glance View
Genexine Inc. is a South Korean biopharmaceutical company that discovers and develops protein-based medicines, with a focus on biologic drugs and antibody-like therapies. Its main work is early-stage research and clinical development rather than large-scale drug manufacturing, so it turns scientific targets into candidate medicines that can be tested in patients. The company makes money mainly by advancing these drug programs through partnerships, licensing deals, and milestone or royalty payments if its medicines are licensed to larger drugmakers. Its customers are not everyday consumers; they are pharmaceutical partners, research collaborators, and eventually patients and hospitals if a drug reaches the market. Genexine’s pipeline has included treatments in cancer, anemia, and immune-related diseases. What makes Genexine’s business model different is that it sits high up in the drug-development chain: it creates the drug candidates and often shares development risk with partners instead of selling finished products directly. That means its value depends on scientific success, clinical trial results, and the ability to secure licensing or commercialization partners for its programs.